Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.
A number of other brokerages have also recently weighed in on KURA. JMP Securities reduced their target price on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a report on Monday, August 11th. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Guggenheim assumed coverage on shares of Kura Oncology in a report on Thursday, September 4th. They set a "neutral" rating for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Tuesday, September 30th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.10.
Check Out Our Latest Research Report on Kura Oncology
Kura Oncology Trading Up 6.9%
Shares of NASDAQ:KURA opened at $10.08 on Wednesday. The stock has a market capitalization of $874.94 million, a price-to-earnings ratio of -4.46 and a beta of 0.32. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $19.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a 50 day moving average price of $7.82 and a 200 day moving average price of $6.75.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. On average, research analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.
Insider Buying and Selling
In other Kura Oncology news, SVP Thomas James Doyle sold 4,541 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $40,596.54. Following the completion of the sale, the senior vice president owned 109,829 shares in the company, valued at $981,871.26. This represents a 3.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Troy Edward Wilson sold 36,615 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $327,338.10. Following the completion of the sale, the chief executive officer owned 246,853 shares of the company's stock, valued at approximately $2,206,865.82. The trade was a 12.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,058 shares of company stock worth $697,839. Insiders own 6.40% of the company's stock.
Institutional Investors Weigh In On Kura Oncology
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BVF Inc. IL lifted its position in Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock worth $51,177,000 after buying an additional 5,186,660 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after purchasing an additional 772,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after purchasing an additional 129,337 shares in the last quarter. EcoR1 Capital LLC raised its holdings in shares of Kura Oncology by 59.1% during the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock valued at $24,234,000 after purchasing an additional 1,559,702 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Kura Oncology by 11.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company's stock valued at $11,623,000 after purchasing an additional 211,470 shares in the last quarter.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
